Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

“…Due to the rarity of LPL/WM, few large phase III randomized clinical trials have been performed to compare different treatment strategies and estimate overall survival. Median overall survival has varied in different series, ranging from 60 to 120 months [4,[7][8][9][10][11][12][13][14]. Treatment of LPL/WM is mainly based on results from phase II trials and expert recommendations [5,6].…”

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients

“…[19][20][21][22][23][24] Indeed, a large proportion of patients die from unrelated causes because of their advanced age at diagnosis. Several studies have shown a negative prognostic influence of high monoclonal IgM levels 22,25 but Dhodapkhar et al 5,26 found that patients with a low monoclonal concentration and a high beta 2 microglobulin had poor outcomes. We did not confirm the other prognostic factors described in the literature, such as high beta 2 microglubulin levels, low albumin levels, anemia or thrombopenia but our series is quite small and the FDR-Cy combination may modified the prognostic factors.…”

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

“…Rituximab, 7 chlorambucil, 8 alkylating agent combinations, 9 R-CHOP (rituximab, CY, doxorubicin (hydroxydaunorubicin), VCR (Oncovin) and prednisone) 10,11 and purine nucleoside analogs 12,13 have all produced high response rates, and many of the responses are durable. Recently, bortezomib 14,15 and bendamustine 16 have both been shown to be highly active in the management of Waldenströ m macroglobulinemia.…”